CPQ and acute myeloid leukemia: An alternative approach to potentiate APN inhibitory activity and overcome resistance in malignancies involves combination therapy, such as co-administration of tosedostat with statins—including simvastatin, fluvastatin, lovastatin, and pravastatin—for the treatment of aminopeptidase-resistant acute myeloid leukemia (AML).130 The therapeutic efficacy of APN inhibitors in cancer treatment can be enhanced through synergy with other anticancer agents, such as paclitaxel.